Loading...
•
Jun 30, 2022
C4 Therapeutics Q2 2022 Earnings Report
Reported financial results for the second quarter ended June 30, 2022 and recent business highlights.
Key Takeaways
C4 Therapeutics reported a revenue of $13.8 million for the second quarter of 2022, compared to $9.8 million for the second quarter of 2021. Net loss for the quarter was $27.4 million, or $0.56 per share, compared to a net loss of $22.6 million, or $0.51 per share, for the second quarter of 2021. Cash, cash equivalents and marketable securities totaled $397.8 million as of June 30, 2022.
Advanced Enrollment in Phase 1/2 Clinical Trial of CFT7455
Dosed First Patient in Phase 1/2 Clinical Trial of CFT8634
Appointed Dr. Laura Bessen and Dr. Donna Grogan to Board of Directors
Cash, Cash Equivalents and Marketable Securities Total $397.8 million as of June 30, 2022; Expected to Provide Runway to End of 2024
Revenue by Segment
Forward Guidance
C4T expects that its cash, cash equivalents and marketable securities as of June 30, 2022, together with future payments expected to be received under existing collaboration agreements, will be sufficient to fund planned operating expenses and capital expenditures to the end of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...